QUALIFYING CONDITIONS
Crohn’s Disease & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide
Compassionate Certification Centers serves Crohn’s disease patients across Pennsylvania and West Virginia with compassionate, judgment-free evaluations. Whether you’re managing abdominal pain, nausea, appetite loss, or other symptoms related to your Crohn’s, our certified physicians are here to help guide your care.
ABOUT Crohn’s Disease
Crohn’s Disease is a type of Inflammatory Bowel Disease (IBD) that causes chronic inflammation in the lining of the digestive tract, which can occur anywhere between the mouth and the anus. There is currently no cure for Crohn’s disease, Pennsylvania and West Virginia both recognize Crohn’s Disease as a qualifying condition for medical marijuana. If you’ve been diagnosed with Crohn’s, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your gastroenterological care.
It’s important to draw a clear distinction at the outset between treating Crohn’s disease and managing its symptoms. Crohn’s is driven by an underlying inflammatory and immune process in the digestive tract, and disease-modifying treatments (such as biologics and immunosuppressants) work specifically to reduce that inflammation and prevent long-term bowel damage. Medical cannabis is not a disease-modifying therapy for Crohn’s and should not replace medications prescribed to control underlying inflammation. Where cannabis may have a role is in managing certain symptoms, such as pain, nausea, and appetite loss alongside, not instead of, standard medical care.
What Is Crohn’s Disease?
Crohn’s disease is one of the two main forms of Inflammatory Bowel Disease (IBD), the other being ulcerative colitis. Unlike ulcerative colitis, which is limited to the colon, Crohn’s can affect any part of the gastrointestinal tract and often involves all layers of the bowel wall, not just the surface lining. Inflammation tends to occur in patches, with healthy tissue between inflamed segments.
Diagnosis
Crohn’s disease is diagnosed through a combination of symptom evaluation and diagnostic testing, generally after other potential causes have been ruled out. The diagnostic process may involve:
- Colonoscopy with biopsy, may reveal granulomas (clusters of inflammatory cells) characteristic of Crohn’s
- Upper endoscopy, if upper GI tract involvement is suspected
- CT or MRI enterography to visualize the small intestine and assess inflammation
- Balloon-assisted enteroscopy for detailed small bowel visualization
- Blood tests for inflammatory markers (CRP, ESR) and to check for anemia or nutritional deficiencies
- Stool studies, including fecal calprotectin, to assess intestinal inflammation and rule out infection
Causes & Risk Factors
The exact cause of Crohn’s disease remains unknown. Diet and stress were once thought to be primary causes but are now understood as factors that may aggravate symptoms rather than cause the disease itself. Current research points to a combination of factors:
- Genetic predisposition, having a first-degree relative with IBD increases risk
- Immune system dysfunction, in which the immune system mistakenly attacks healthy gut tissue
- Environmental factors, including smoking (a known risk factor specifically for Crohn’s)
- Alterations in gut microbiome composition
Crohn’s-Related Diagnoses That May Qualify
Pennsylvania and West Virginia recognize Crohn’s disease and its clinical subtypes as qualifying conditions, including:
- Crohn’s Disease of the Small Intestine and/or Large Intestine
- Crohn’s (Granulomatous) Colitis
- Gastroduodenal Crohn’s Disease
- Ileitis
- Ileocolitis
- Jejunoileitis
- Regional Enteritis
Unsure whether your specific diagnosis qualifies? Our team can review your medical records and help determine eligibility.
Common Symptoms of Crohn’s Disease
Crohn’s symptoms vary significantly depending on which part of the digestive tract is affected and the severity of inflammation. Common symptoms include:
- Abdominal pain and cramping
- Persistent or extreme diarrhea
- Fever
- Weight loss and malnutrition
- Nausea
- Fatty, oily stools (steatorrhea)
- Anemia (often from chronic blood loss or malabsorption)
- Fatigue
- Joint pain
- Skin rashes (including erythema nodosum)
- Eye inflammation (uveitis, episcleritis)
- Mouth ulcers
- Increased risk of blood clots
- Anxiety and stress related to disease unpredictability
Medical Cannabis & Crohn’s Disease: What the Research Currently Shows
Crohn’s disease is one of the few qualifying conditions where actual randomized controlled trials (RCTs) of cannabis exist — most cannabis research relies on observational or preclinical data. This makes the evidence base unusually direct, and it is important to present it accurately, including its most clinically significant finding: cannabis appears to improve how patients feel without measurably healing the underlying inflammation. This section is informational only and does not constitute medical advice.
1. The Critical Distinction: Symptom Relief vs. Disease Healing
This is the single most important finding in Crohn’s cannabis research. A landmark 2021 randomized, double-blind, placebo-controlled trial led by Dr. Timna Naftali (published in the Journal of Crohn’s and Colitis) gave CBD-rich cannabis oil to Crohn’s patients over 8 weeks. The trial found a significant improvement in clinical symptoms and patient-reported quality of life — but no significant improvement in endoscopic markers of inflammation compared to placebo. In other words, patients felt better, but objective measures of bowel inflammation did not improve. The same research group found an identical pattern in a companion trial in ulcerative colitis patients.
This distinction matters enormously for patients: feeling better is valuable, but it should not be mistaken for the disease itself being controlled. Continuing to use disease-modifying medications as prescribed — even if cannabis is helping with symptoms — remains essential to prevent silent disease progression and long-term bowel damage.
2. What the Clinical Trial Evidence Shows Overall
A 2025 systematic review and meta-analysis of randomized controlled trials in Crohn’s disease (published in the Irish Journal of Medical Science) found that cannabis use was associated with significantly higher clinical remission rates at 8 weeks compared to placebo across the available trials. However, the review explicitly noted that improvements in objective inflammatory markers and endoscopic findings were inconsistent across the included studies, and concluded that larger, standardized studies are still needed before cannabis-based treatment recommendations can be made with confidence.
An earlier foundational study by the same Israeli research group (Naftali et al., 2013, Clinical Gastroenterology and Hepatology) found that inhaled cannabis induced clinical response in patients with treatment-resistant Crohn’s disease, with several patients achieving clinical remission. This was a small (n=21), short-duration study and has not been replicated at scale.
3. Official Gastroenterology Society Guidance
The Canadian Association of Gastroenterology (CAG) issued a formal position statement on cannabis use in gastroenterological disorders, concluding that cannabis does not appear to alter the underlying course of IBD — for better or worse — based on current evidence, and explicitly recommending that medical cannabis should not replace approved, disease-modifying IBD therapies. The statement notes that concurrent use of cannabis for symptom control alongside approved therapies may be reasonable for some patients, provided the risk of harm is low and use is medically supervised.
4. The Endocannabinoid System & Gut Inflammation: Biological Rationale
The gastrointestinal tract contains a dense network of endocannabinoid receptors, providing biological plausibility for cannabinoids to influence gut symptoms such as pain, motility, and nausea. This is an area of ongoing preclinical and translational research. Biological plausibility is not the same as proven clinical benefit, and the CAG and other reviewers caution that mechanistic rationale should not be mistaken for clinical evidence of disease control.
5. Important Safety Considerations
Cannabis use carries its own risks that Crohn’s patients should discuss with their gastroenterologist, including the potential for cannabis hyperemesis syndrome (a cycle of severe nausea and vomiting associated with chronic heavy cannabis use) and interactions with immunosuppressive medications commonly prescribed for IBD. Patients with Crohn’s disease, particularly those on biologic or immunosuppressive therapy, should always coordinate any cannabis use with their treating physician.
Medical Disclaimer: Medical cannabis is not a disease-modifying treatment for Crohn’s disease and has not been approved by the FDA to treat, cure, or alter the course of Crohn’s or any form of IBD. Clinical trial evidence shows cannabis may improve symptoms without measurably reducing underlying inflammation. The information in this section is provided for general informational purposes only and does not constitute medical advice. Patients should never delay, reduce, or discontinue prescribed IBD therapy based on symptom improvement from cannabis. Always consult your gastroenterologist and a certified medical marijuana physician before incorporating cannabis into your care plan.
APPLICATION GUIDE
How to Get a Medical Marijuana Card for Crohn’s Disease in Pennsylvania or West Virginia
Both Pennsylvania and West Virginia recognize Crohn’s disease as a qualifying condition. The certification process with Compassionate Certification Centers is straightforward:
Step 1: Register over the phone or online, next-day appointments are often available.
Step 2: Meet with a certified medical marijuana physician who will review your Crohn’s diagnosis, current treatment plan, and symptom profile to determine whether certification is appropriate.
Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.
Our physicians are experienced in working alongside gastroenterology teams and can help ensure that any cannabis-based approach is considered within the full context of your existing treatment, including a review of potential interactions with biologic or immunosuppressive therapy.
SOURCES & REFERENCES
The following peer-reviewed publications, randomized controlled trials, and clinical society position statements informed the research summary above. All sources are publicly accessible via PubMed or PMC. No source should be interpreted as establishing medical cannabis as a disease-modifying treatment for Crohn’s disease.
Key Randomized Controlled Trials
[1] Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. (2021). “Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial.” Journal of Crohn’s and Colitis, 15(11), 1799–1806. PubMed ID: 33858011.
https://pubmed.ncbi.nlm.nih.gov/33858011/
The landmark double-blind, placebo-controlled RCT in this field. Found significant clinical symptom improvement with CBD-rich cannabis oil, but no significant improvement in endoscopic (objective inflammatory) findings versus placebo. This is the single most important study for understanding what cannabis can and cannot do for Crohn’s disease.
[2] Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. (2021). “Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.” PLOS ONE, 16(2), e0246871. PubMed ID: 33571293.
https://doi.org/10.1371/journal.pone.0246871
A companion RCT in ulcerative colitis (the other major form of IBD) by the same research group, finding an identical pattern: clinical symptom improvement without corresponding endoscopic healing. Included here because it reinforces the consistency of this critical finding across IBD subtypes.
[3] Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. (2013). “Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.” Clinical Gastroenterology and Hepatology, 11(10), 1276–1280.e1. PubMed ID: 23648372.
An earlier, smaller (n=21) placebo-controlled study finding that inhaled cannabis induced clinical response, with some patients achieving remission, in treatment-resistant Crohn’s patients. Small sample size limits generalizability.
Systematic Reviews & Meta-Analyses
[4] (2025). “Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials (RCTs).” Irish Journal of Medical Science.
https://doi.org/10.1007/s11845-024-03844-w
A 2025 meta-analysis pooling available RCTs, finding higher clinical remission rates with cannabis versus placebo at 8 weeks, while explicitly noting inconsistent improvement in inflammatory and endoscopic markers across studies. Concludes that larger, standardized trials are needed before firm clinical recommendations can be made.
Clinical Society Guidance
[5] Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, Congly SE. (2019). “Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.” Journal of the Canadian Association of Gastroenterology, 2(2), 37–43. PMC ID: PMC6507278.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6507278/
The leading clinical society position statement on this topic. States that cannabis does not appear to alter the underlying course of IBD and recommends that medical cannabis should not replace approved IBD therapies. Notes that concurrent symptom-focused use alongside standard therapy may be reasonable for some patients under medical supervision. This is the most authoritative clinical guidance source for this page.
[6] Swaminath A, Berlin EP, Cheifetz A, et al. (2019). “Insights into the role of cannabis in the management of inflammatory bowel disease.” Crohn’s & Colitis 360 / PMC ID: PMC6727090.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6727090/
A review summarizing the CAG position and broader IBD/cannabis literature, reiterating that cannabis does not alter disease course and should not replace approved therapy. Also discusses populations who should avoid cannabis use, including those with relevant psychiatric or family history.
